Microarray Profiling of Antibody Responses against Simian-Human Immunodeficiency Virus: Postchallenge Convergence of Reactivities Independent of Host Histocompatibility Type and Vaccine Regimen

ABSTRACT We developed antigen microarrays to profile the breadth, strength, and kinetics of epitope-specific antiviral antibody responses in vaccine trials with a simian-human immunodeficiency virus (SHIV) model for human immunodeficiency virus (HIV) infection. These arrays contained 430 distinct proteins and overlapping peptides spanning the SHIV proteome. In macaques vaccinated with three different DNA and/or recombinant modified vaccinia virus Ankara (rMVA) vaccines encoding Gag-Pol or Gag-Pol-Env, these arrays distinguished vaccinated from challenged macaques, identified three novel viral epitopes, and predicted survival. Following viral challenge, anti-SHIV antibody responses ultimately converged to target eight immunodominant B-cell regions in Env regardless of vaccine regimen, host histocompatibility type, and divergent T-cell specificities. After challenge, responses to nonimmunodominant epitopes were transient, while responses to dominant epitopes were gained. These data suggest that the functional diversity of anti-SHIV B-cell responses is highly limited in the presence of persisting antigen.

[1]  Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine , 2001, Science.

[2]  D. Grandgenett,et al.  Folding of the multidomain human immunodeficiency virus type‐I integrase , 1994, Protein science : a publication of the Protein Society.

[3]  K. Sepkowitz,et al.  AIDS--the first 20 years. , 2001, The New England journal of medicine.

[4]  J. Sodroski,et al.  Persistent infection of macaques with simian-human immunodeficiency viruses , 1995, Journal of virology.

[5]  A. Simon,et al.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.

[6]  Ali Ahmad,et al.  Antibody‐dependent cellular cytotoxicity in HIV infections , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  R. M. Hendry,et al.  High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. , 1991, AIDS research and human retroviruses.

[8]  D. Burton.  Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.

[9]  R. Kennedy,et al.  Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. , 1986, Science.

[10]  P. Brown,et al.  Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions , 2001, Genome Biology.

[11]  J. Mascola,et al.  Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. , 1998, The Journal of infectious diseases.

[12]  B. Walker,et al.  CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. , 1997, Advances in immunology.

[13]  M. Cohn,et al.  The Protection: The Unit of Humoral Immunity Selected by Evolution , 1990, Immunological Reviews.

[14]  S. Pincus,et al.  Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection. , 1994, The Journal of clinical investigation.

[15]  M. Bukrinsky,et al.  Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Altavilla,et al.  HIV type 1 extracellular Tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. , 1995, AIDS research and human retroviruses.

[17]  S. Zolla-Pazner,et al.  Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies , 1991, Journal of virology.

[18]  J. Sodroski,et al.  Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys , 1997, Journal of virology.

[19]  P. Earl,et al.  Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines , 2002, Journal of Virology.

[20]  H. M. Geysen,et al.  Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Gritz,et al.  Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. , 1991, AIDS.

[22]  F. Alt,et al.  Development of the primary antibody repertoire. , 1987, Science.

[23]  J. Nelson,et al.  Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. , 1987, The Journal of infectious diseases.

[24]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[25]  C. Y. Wang,et al.  Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[27]  B. Walker,et al.  Anti-HIV cellular immunity: recent advances towards vaccine design. , 1999, AIDS.

[28]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[29]  B. Walker,et al.  HIV Molecular Immunology 2001 , 2001 .

[30]  C. Hanson,et al.  Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. Collaborating Investigators. , 1991, AIDS.

[31]  R. Brasseur,et al.  Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. , 1990, Intervirology.

[32]  H. Robinson,et al.  A new generation of HIV vaccines. , 2002, Trends in molecular medicine.

[33]  Q. Sattentau,et al.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. , 1999, AIDS.

[34]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[35]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  B. Graham,et al.  Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. , 1997, Journal of Immunology.

[37]  P. Brown,et al.  Autoantigen microarrays for multiplex characterization of autoantibody responses , 2002, Nature Medicine.

[38]  P. Earl,et al.  Critical Role for Env as well as Gag-Pol in Control of a Simian-Human Immunodeficiency Virus 89.6P Challenge by a DNA Prime/Recombinant Modified Vaccinia Virus Ankara Vaccine , 2002, Journal of Virology.

[39]  A. Coutinho,et al.  Functional diversity and clonal frequencies of reactivity in the available antibody repertoire , 1998, European journal of immunology.

[40]  W. Blattner,et al.  Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. , 1993, The Journal of clinical investigation.

[41]  S. Lemon,et al.  Immunogenic domains of hepatitis delta virus antigen: peptide mapping of epitopes recognized by human and woodchuck antibodies , 1990, Journal of virology.

[42]  L. van der Hoek,et al.  Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. , 1991, Virology.

[43]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Moore,et al.  Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. , 1994, AIDS research and human retroviruses.

[45]  J. Hilliard,et al.  Identification of a herpes B virus-specific glycoprotein d immunodominant epitope recognized by natural and foreign hosts. , 2002, The Journal of infectious diseases.

[46]  J. Hurwitz,et al.  Effect of natural HIV-1 envelope V1-V2 sequence diversity on the binding of V3-specific and non-V3-specific antibodies. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[47]  J. Sodroski,et al.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys , 1996, Journal of virology.

[48]  K. Okuda,et al.  Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes , 1997, Journal of virology.

[49]  A. von Brunn,et al.  Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. , 1993, Vaccine.

[50]  R. Weiss,et al.  An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies , 1989, Nature.